JP2013032319A - Method for controlling keratotic plug regeneration, and kit for controlling keratotic plug regeneration - Google Patents
Method for controlling keratotic plug regeneration, and kit for controlling keratotic plug regeneration Download PDFInfo
- Publication number
- JP2013032319A JP2013032319A JP2011169751A JP2011169751A JP2013032319A JP 2013032319 A JP2013032319 A JP 2013032319A JP 2011169751 A JP2011169751 A JP 2011169751A JP 2011169751 A JP2011169751 A JP 2011169751A JP 2013032319 A JP2013032319 A JP 2013032319A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- skin
- regeneration
- horn
- horn plug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008929 regeneration Effects 0.000 title claims abstract description 63
- 238000011069 regeneration method Methods 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 21
- -1 polyoxyethylene Polymers 0.000 claims abstract description 44
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 31
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 18
- 239000000194 fatty acid Substances 0.000 claims abstract description 18
- 229930195729 fatty acid Natural products 0.000 claims abstract description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 11
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000015165 citric acid Nutrition 0.000 claims abstract description 9
- 239000004310 lactic acid Substances 0.000 claims abstract description 9
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 5
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims abstract description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000001630 malic acid Substances 0.000 claims abstract description 4
- 235000011090 malic acid Nutrition 0.000 claims abstract description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 18
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 10
- 229960000401 tranexamic acid Drugs 0.000 claims description 10
- 238000007788 roughening Methods 0.000 claims description 9
- 229960003237 betaine Drugs 0.000 claims description 8
- 229920001451 polypropylene glycol Polymers 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940068065 phytosterols Drugs 0.000 claims description 3
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- 239000012459 cleaning agent Substances 0.000 abstract description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 2
- 230000037336 dry skin Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 28
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- 239000012071 phase Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 7
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 229960000448 lactic acid Drugs 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 229940093915 gynecological organic acid Drugs 0.000 description 6
- 229940094506 lauryl betaine Drugs 0.000 description 6
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 6
- 235000005985 organic acids Nutrition 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000011538 cleaning material Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical group CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical group C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960004275 glycolic acid Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 229960005137 succinic acid Drugs 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- LPDGWMLCUHULJF-UHFFFAOYSA-N 3-piperidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCCC1 LPDGWMLCUHULJF-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940071124 cocoyl glutamate Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- MTJZWYHTZFVEGI-INIZCTEOSA-N (2s)-2-(tetradecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O MTJZWYHTZFVEGI-INIZCTEOSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- LQXBZWFNAKZUNM-UHFFFAOYSA-N 16-methyl-1-(16-methylheptadecoxy)heptadecane Chemical compound CC(C)CCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC(C)C LQXBZWFNAKZUNM-UHFFFAOYSA-N 0.000 description 1
- HVHARNWCHRYVII-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;2-ethylhexanoic acid Chemical compound OCC(CO)(CO)CO.CCCCC(CC)C(O)=O HVHARNWCHRYVII-UHFFFAOYSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- HQWVJPHAUFZXJQ-UHFFFAOYSA-N 2-(dimethylazaniumyl)-2-ethyltetradecanoate Chemical compound CCCCCCCCCCCCC(CC)([NH+](C)C)C([O-])=O HQWVJPHAUFZXJQ-UHFFFAOYSA-N 0.000 description 1
- LNCJHVLXANMHHD-UHFFFAOYSA-N 2-[2-heptadecyl-1-(2-hydroxyethyl)-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound CCCCCCCCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O LNCJHVLXANMHHD-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- CYRUSJUGGJVQEE-UHFFFAOYSA-N 2-ethyl-2-(hydroxymethyl)propane-1,3-diol;2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O.CCC(CO)(CO)CO CYRUSJUGGJVQEE-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- ZZKFPIOJAOEMQL-UHFFFAOYSA-N 5-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(O)C(C(O)=O)=C1 ZZKFPIOJAOEMQL-UHFFFAOYSA-N 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LDDUCKDUDZVHLN-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-(16-methylheptadecanoyloxy)propoxy]propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCC(C)C LDDUCKDUDZVHLN-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 229940090934 diphenylsiloxy phenyl trimethicone Drugs 0.000 description 1
- JOLYVEWZEPKDIJ-UTLKBRERSA-L dipotassium;(2s)-2-(dodecanoylamino)pentanedioate Chemical compound [K+].[K+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O JOLYVEWZEPKDIJ-UTLKBRERSA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- MMGBQGRJNNZECX-SCGRZTRASA-L magnesium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CCCNC(N)=N.[O-]C(=O)[C@@H](N)CCCNC(N)=N MMGBQGRJNNZECX-SCGRZTRASA-L 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QPQANCNBWQXGTQ-UHFFFAOYSA-N trihydroxy(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](O)(O)O QPQANCNBWQXGTQ-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は角栓再生抑制方法および角栓再生抑制キットに関する。さらに詳しくは、非常に高い角栓再生抑制効果を奏する角栓再生抑制方法および角栓再生抑制キットに関する。 The present invention relates to a method for inhibiting the regeneration of horn plugs and a kit for inhibiting horn plug regeneration. More specifically, the present invention relates to a method for suppressing horn plug regeneration and a kit for suppressing horn plug regeneration that exhibit a very high effect for suppressing horn plug regeneration.
角栓の悩みは、女性の肌悩みの中でも上位に挙げられる項目である。角栓は、皮脂と剥離した角層の混合物が毛孔に詰まったものであり(非特許文献1)、これが成長すると白く詰まり、あるいは産毛や汚れを含むと黒く詰まって、ブツブツ状となって目立ち、見た目にもまた触感としてもざらついて好ましくない。また、これを放置すると肌トラブルにもつながるといわれている。 The problem of horn plugs is one of the top items among women's skin problems. A horn plug is a mixture of sebum and exfoliated horny layer clogged in the pores (Non-Patent Document 1). It is not preferable because it looks and feels rough. It is also said that leaving this untreated leads to skin problems.
対応策としては、洗浄料やパックなどで除去するのが一般的であり、非常に多くの商品が販売されている。角栓除去に関する従来技術文献も数多く、例えばN−アシルアミノ酸塩を含むもの(特許文献1)や、ラウロイルサルコシンなどを含むもの(特許文献2)、常温液状油分とN,N,N’,N’−テトラキス(2−ヒドロキシプロピル)エチレンジアミン、ノニオン界面活性剤などの組合せ(特許文献3)、ダイマー酸のジエステルとモノ脂肪酸ポリグリセリルの組合せ(特許文献4)、ダイマー酸のジエステルとポリオキシエチレン脂肪酸グリセリルの組合せ(特許文献5)、炭素原子数6〜20の二塩基酸ジエステル(特許文献6)などが挙げられる。しかしながら、その除去効率はあまり高いものではなく、除去してもまた1週間程度で再生してきてしまうこともあり、パックでの処理を繰り返すことで肌荒れしてしまうことも多かった。 As a countermeasure, it is common to remove them with cleaning materials or packs, and a great many products are sold. There are many prior art documents related to horn plug removal, for example, those containing N-acylamino acid salts (Patent Document 1), those containing lauroyl sarcosine (Patent Document 2), room temperature liquid oil and N, N, N ′, N Combination of '-tetrakis (2-hydroxypropyl) ethylenediamine, nonionic surfactant, etc. (Patent Document 3), combination of dimer acid diester and mono fatty acid polyglyceryl (Patent Document 4), dimer acid diester and polyoxyethylene fatty acid glyceryl (Patent Document 5), dibasic acid diester having 6 to 20 carbon atoms (Patent Document 6), and the like. However, the removal efficiency is not so high, and even if it is removed, it may be regenerated in about one week, and the skin often becomes rough by repeating the processing with the pack.
これまでに、角栓の再生抑制に関しては、タンニン酸、乳酸、クエン酸、酒石酸、グルタミン酸などの有機酸類およびその塩に効果があることが知られている(特許文献7〜8参照)。しかしながら、その効果はなかなか実感しにくいのが実情で、市場においても、収斂化粧水など毛穴の引き締めをうたう商品はあるものの、角栓を再生しにくくすることをうたった商品は存在していなかった。また、有機酸単独では肌荒れや感覚刺激が起こる場合があり、化粧品として一般的に使用することは難しかった。 So far, it has been known that organic acids such as tannic acid, lactic acid, citric acid, tartaric acid, and glutamic acid and salts thereof are effective in suppressing regeneration of horn plugs (see Patent Documents 7 to 8). However, the effect is quite difficult to realize, and even in the market there are products that tighten pores, such as astringent lotion, but there are no products that claim to make it difficult to regenerate horn plugs. . In addition, organic acids alone may cause rough skin and sensory irritation, and it is difficult to use them generally as cosmetics.
本発明は上記事情に鑑みてなされたもので、肌荒れを起こさずに、極めて効果的に角栓の再生を抑制することができる方法、および該方法に用いられる角栓再生抑制キットを提供することを目的とする。 The present invention has been made in view of the above circumstances, and provides a method for suppressing the regeneration of horn plugs extremely effectively without causing rough skin, and a horn plug regeneration suppression kit used in the method. With the goal.
上記課題を解決するために本発明者らは研究を重ねた結果、特定の洗浄料と特定の角栓再生抑制剤とを用いることで、肌荒れを起こさずに、角栓の再生抑制効果が非常に高まることを見出し、本発明を完成するに至った。 As a result of repeated studies by the present inventors to solve the above problems, the use of a specific cleaning material and a specific horn plug regeneration inhibitor has an extremely effective effect of suppressing the regeneration of horn plugs without causing rough skin. As a result, the present invention has been completed.
すなわち本発明は、ポリオキシエチレン脂肪酸エステルを含む皮膚洗浄料を肌へ適用した後に、乳酸、コハク酸、クエン酸、リンゴ酸、サリチル酸、ピロリドンカルボン酸、グリコール酸、およびそれらの塩の中から選ばれる1種または2種以上を含む角栓再生抑制剤を皮膚へ適用することを特徴とする、角栓再生抑制方法に関する。 That is, the present invention is selected from lactic acid, succinic acid, citric acid, malic acid, salicylic acid, pyrrolidone carboxylic acid, glycolic acid, and salts thereof after applying a skin cleanser containing polyoxyethylene fatty acid ester to the skin. The present invention relates to a method for inhibiting the regeneration of horn plugs, which comprises applying to the skin a horn plug regeneration inhibitor containing one or more of the above.
また本発明は、角栓抑制剤中にさらに脂肪酸石鹸、高級アルキル硫酸エステル塩、N−アシルグルタミン酸塩、N−アシル低級アルキルタウリン塩、ベタイン系界面活性剤、およびポリオキシアルキレンフィトステロールの中から選ばれる1種または2種以上の界面活性剤を含む、上記角栓再生抑制方法に関する。 In the present invention, the horn plug inhibitor is further selected from fatty acid soaps, higher alkyl sulfates, N-acyl glutamates, N-acyl lower alkyl taurates, betaine surfactants, and polyoxyalkylene phytosterols. It is related with the said square plug reproduction | regeneration suppression method containing the 1 type, or 2 or more types of surfactant.
また本発明は、角栓抑制剤中にさらに抗肌荒れ剤を含む、上記角栓再生抑制方法に関する。 The present invention also relates to the above-described method for inhibiting regeneration of horn plugs, further comprising an anti-skin roughening agent in the horn plug inhibitor.
また本発明は、抗肌荒れ剤が、ポリオキシエチレン/ポリオキシプロピレン/ジメチルエーテル(=「PEG/PPGジメチルエーテル」)、トラネキサム酸、およびパントテニルエチルエーテルの中から選ばれる1種または2種以上である、上記角栓再生抑制方法に関する。 In the present invention, the anti-skin roughening agent is one or more selected from polyoxyethylene / polyoxypropylene / dimethyl ether (= “PEG / PPG dimethyl ether”), tranexamic acid, and pantothenyl ethyl ether. The present invention also relates to the above-mentioned method for suppressing the regeneration of horn plugs.
また本発明は、上記の皮膚洗浄料と角栓再生抑制剤とからなる、角栓再生抑制キットに関する。 In addition, the present invention relates to a horn plug regeneration suppression kit comprising the above skin cleansing agent and horn plug regeneration inhibitor.
本発明により、非常に高い角栓再生抑制効果を奏する角栓再生抑制方法および角栓再生抑制キットが提供される。 INDUSTRIAL APPLICABILITY According to the present invention, there are provided a horn plug regeneration suppression method and a horn plug regeneration suppression kit that exhibit an extremely high effect of suppressing horn plug regeneration.
以下、本発明について詳述する。 Hereinafter, the present invention will be described in detail.
<皮膚洗浄料>
本発明に用いられる皮膚洗浄料は、有効成分としてポリオキシエチレン脂肪酸エステルを含む。ポリオキシエチレン脂肪酸エステルとしては、オレイン酸残基、イソステアリン酸残基、ラウリン酸残基から選ばれる1種以上の脂肪酸残基を有する、POEソルビタン脂肪酸エステル、POE脂肪酸エステル、POEグリセリン脂肪酸エステル、POEプロピレングリコール脂肪酸エステル、POE硬化ヒマシ油系界面活性剤、ソルビタン系界面活性剤、POEオレイルエーテル、POEラウリルエーテル、POEイソステアリルエーテル等が挙げられる。ただしこれら例示に限定されるものでない。ポリオキシエチレン脂肪酸エステルは1種または2種以上を用いることができる。
<Skin cleansing agent>
The skin cleanser used in the present invention contains a polyoxyethylene fatty acid ester as an active ingredient. Examples of the polyoxyethylene fatty acid ester include POE sorbitan fatty acid ester, POE fatty acid ester, POE glycerin fatty acid ester, POE having at least one fatty acid residue selected from oleic acid residue, isostearic acid residue, and lauric acid residue. Examples include propylene glycol fatty acid ester, POE hydrogenated castor oil surfactant, sorbitan surfactant, POE oleyl ether, POE lauryl ether, and POE isostearyl ether. However, it is not limited to these examples. One or more polyoxyethylene fatty acid esters can be used.
皮膚洗浄料中におけるポリオキシエチレン脂肪酸エステルの配合量は1〜60質量%が好ましく、より好ましくは5〜40質量%である。上記配合量範囲とすることで、角栓再生抑制剤との併用において、極めて優れた角栓再生抑制効果を得ることができる。配合量が1質量%未満では成分としての効果を十分に発揮することができず、一方、60質量%を超えて配合しても、配合量に見合った効果の増大は望めない。 1-60 mass% is preferable, and, as for the compounding quantity of the polyoxyethylene fatty acid ester in a skin cleansing material, More preferably, it is 5-40 mass%. By setting it as the said compounding quantity range, in the combined use with a horn plug regeneration inhibitor, a very excellent horn plug regeneration inhibitory effect can be obtained. If the blending amount is less than 1% by mass, the effect as a component cannot be sufficiently exhibited. On the other hand, even if blending exceeds 60% by mass, an increase in the effect commensurate with the blending amount cannot be expected.
皮膚洗浄料は、オイルタイプ、フォームタイプ、液状タイプ等のいずれの基剤を用いてもよい。本発明では特にオイルタイプの液状製剤(クレンジングオイル等)が好ましく用いられる。オイルタイプの洗浄料(油性洗浄料)の場合、上記必須成分の他に、常温で液状の油分が主成分として配合される。このような液状油分としては、例えば、流動パラフィン(ミネラルオイル)、スクワラン、オリフィンオリゴマー、軽質イソパラフィン等の炭化水素油;2−エチルヘキサン酸トリグリセリド、2−エチルヘキサン酸セチル、2−エチルヘキサン酸ペンタエリスリトール、2−エチルヘキサン酸トリメチロールプロパン、パルミチン酸2−エチルヘキシル、イソノナン酸イソセチル、ミリスチン酸イソプロピル等のエステル油;ホホバ油、オリーブ油、マカデミアナッツ油、綿実油、茶実油、サフラワー油、米ヌカ油等の天然系植物油;デカメチルペンタシクロシロキサン、オクタメチルテトラシクロシロキサン、ジメチルシロキサン、メチルフェニルシロキサン等のシリコーン油などが挙げられる。 Any base such as an oil type, a foam type, and a liquid type may be used as the skin cleansing material. In the present invention, an oil type liquid preparation (cleansing oil or the like) is particularly preferably used. In the case of an oil-type cleaning material (oil-based cleaning material), in addition to the above essential components, a liquid oil component at room temperature is blended as a main component. Examples of such liquid oil include hydrocarbon oils such as liquid paraffin (mineral oil), squalane, olifin oligomer, and light isoparaffin; 2-ethylhexanoic acid triglyceride, 2-ethylhexanoic acid cetyl, 2-ethylhexanoic acid Ester oil such as pentaerythritol, triethylolpropane 2-ethylhexanoate, 2-ethylhexyl palmitate, isocetyl isononanoate, isopropyl myristate; jojoba oil, olive oil, macadamia nut oil, cottonseed oil, teaseed oil, safflower oil, rice bran Examples include natural vegetable oils such as oils; silicone oils such as decamethylpentacyclosiloxane, octamethyltetracyclosiloxane, dimethylsiloxane, and methylphenylsiloxane.
液状油分を配合する場合、皮膚洗浄料中に50〜95質量%の範囲で配合するのが好ましく、より好ましくは60〜80質量%である。配合量が50質量%では成分としての効果を十分に発揮することはできず、一方、95質量%を越えて配合しても、配合量に見合った効果の増大は望めない。 When mix | blending a liquid oil component, it is preferable to mix | blend in the range of 50-95 mass% in a skin cleansing material, More preferably, it is 60-80 mass%. If the blending amount is 50% by mass, the effect as a component cannot be sufficiently exhibited. On the other hand, even if blending exceeds 95% by mass, an increase in the effect commensurate with the blending amount cannot be expected.
またこれら液状油分の他に配合され得る成分として、通常、化粧料や医薬品の分野で配合されている各種成分を、本発明効果を損なわない範囲で添加することができる。このような成分としては、例えば、エタノール、イソプロピルアルコール等の低級アルコール類、グリセリン、1,3−ブチレングリコール、イソプレングリコール、1,3−ブタンジオール、ジプロピレングリコール、プロピレングリコール等の多価アルコール類、アニオン性界面活性剤、N−アルキル−N,N−ジメチルアミノ酢酸ベタイン、アルキルジメチルアミンオキサイド等の両性界面活性剤、カチオン性界面活性剤、非イオン性界面活性剤、殺菌剤、紫外線吸収剤、酸化防止剤、香料、水等が挙げられる。 Further, as components that can be blended in addition to these liquid oils, various components that are usually blended in the field of cosmetics and pharmaceuticals can be added within a range that does not impair the effects of the present invention. Examples of such components include lower alcohols such as ethanol and isopropyl alcohol, and polyhydric alcohols such as glycerin, 1,3-butylene glycol, isoprene glycol, 1,3-butanediol, dipropylene glycol, and propylene glycol. , Anionic surfactants, amphoteric surfactants such as N-alkyl-N, N-dimethylaminoacetic acid betaine, alkyldimethylamine oxide, cationic surfactants, nonionic surfactants, bactericides, UV absorbers , Antioxidants, fragrances, water and the like.
<角栓再生抑制剤>
[有機酸類]
本発明に用いられる角栓再生抑制剤は、乳酸、コハク酸、クエン酸、リンゴ酸、サリチル酸、ピロリドンカルボン酸、グリコール酸の中から選ばれる有機酸、あるいはそれらの塩を含む。塩としては、一般に化粧料に用いられ得るものであれば特に限定するものでなく、例えばアルカリ金属塩(ナトリウム塩、カリウム塩、リチウム塩、等)、アルカリ土類金属塩(カルシウム塩、マグネシウム塩、等)、アンモニウム塩、有機アミン塩(モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、等)などが挙げられる。中でも乳酸、コハク酸、サリチル酸、ピロリドンカルボン酸、またはこれらの塩が好ましい。これら有機酸類は1種または2種以上を用いることができる。
<Square plug regeneration inhibitor>
[Organic acids]
The horn plug regeneration inhibitor used in the present invention contains an organic acid selected from lactic acid, succinic acid, citric acid, malic acid, salicylic acid, pyrrolidone carboxylic acid and glycolic acid, or a salt thereof. The salt is not particularly limited as long as it can be generally used in cosmetics. For example, alkali metal salts (sodium salt, potassium salt, lithium salt, etc.), alkaline earth metal salts (calcium salt, magnesium salt) Etc.), ammonium salts, organic amine salts (monoethanolamine salts, diethanolamine salts, triethanolamine salts, etc.). Of these, lactic acid, succinic acid, salicylic acid, pyrrolidone carboxylic acid, or salts thereof are preferred. These organic acids can be used alone or in combination of two or more.
上記有機酸類の配合量は、本発明で用いる角栓再生抑制剤中に0.001〜20質量%が好ましく、より好ましくは0.05〜5質量%である。0.001質量%未満では(a)成分としての効果を十分に発揮することができず、一方、20質量%を超えて配合しても、配合量に見合った効果の増大は望めない。 The blending amount of the organic acids is preferably 0.001 to 20% by mass, more preferably 0.05 to 5% by mass in the horn plug regeneration inhibitor used in the present invention. If it is less than 0.001% by mass, the effect as the component (a) cannot be sufficiently exhibited. On the other hand, even if it exceeds 20% by mass, an increase in the effect commensurate with the compounding amount cannot be expected.
[界面活性剤]
本発明で用いる角栓再生抑制剤には、上記有機酸類の他に、脂肪酸石鹸、高級アルキル硫酸エステル塩、N−アシルグルタミン酸塩、N−アシル低級アルキルタウリン塩、ベタイン系界面活性剤、およびポリオキシアルキレンフィトステロールの中から選ばれる界面活性剤を含有するのが好ましい。
[Surfactant]
In addition to the above organic acids, the horn plug regeneration inhibitor used in the present invention includes fatty acid soap, higher alkyl sulfate ester salt, N-acyl glutamate salt, N-acyl lower alkyl taurine salt, betaine surfactant, It is preferable to contain a surfactant selected from oxyalkylene phytosterols.
脂肪酸石鹸としては、ラウリン酸ナトリウム、ラウリン酸カリウム、パルミチン酸ナトリウム、パルミチン酸カリウム等が挙げられる。 Examples of the fatty acid soap include sodium laurate, potassium laurate, sodium palmitate, potassium palmitate and the like.
高級アルキル硫酸エステル塩としては、ラウリル硫酸ナトリウム、ラウリル硫酸カリウム等が挙げられる。 Examples of higher alkyl sulfate salts include sodium lauryl sulfate and potassium lauryl sulfate.
N−アシルグルタミン酸塩としては、N−ラウロイルグルタミン酸ナトリウム、N−ラウロイルグルタミン酸カリウム、N−ココイルグルタミン酸ジナトリウム、N−ココイルグルタミン酸時カリウム、N−ミリストイル−L−グルタミン酸ナトリウム、N−ミリストイル−L−グルタミン酸モノカリウム等が挙げられる。 Examples of N-acylglutamate include sodium N-lauroylglutamate, potassium N-lauroylglutamate, disodium N-cocoylglutamate, potassium when N-cocoylglutamate, N-myristoyl-L-glutamate, N-myristoyl-L-glutamic acid And monopotassium.
N−アシル低級アルキルタウリン塩としては、特にN−アシルメチルタウリン塩が好ましく、具体例として、N−ヤシ油脂肪酸−N−メチルタウリンナトリウム、N−ヤシ油脂肪酸−N−メチルタウリントリエタノールアミン、N−ヤシ油脂肪酸−N−メチルタウリンマグネシウム等が挙げられる。 As the N-acyl lower alkyl taurine salt, an N-acyl methyl taurine salt is particularly preferable. Specific examples include N-coconut oil fatty acid-sodium N-methyltaurine, N-coconut oil fatty acid-N-methyltaurine triethanolamine, N-coconut oil fatty acid-N-methyl taurine magnesium etc. are mentioned.
ベタイン系界面活性剤としては、2−ヘプタデシル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酪酸ベタイン、アルキルベタイン(例えば、ラウリルベタイン等)、アミドベタイン、スルホベタイン等が挙げられる。またそれらの塩が挙げられる。塩としてはナトリウム塩、カリウム塩等が挙げられるが、これら例示に限定されるものでない。 Examples of betaine surfactants include 2-heptadecyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryl dimethylaminobutyric acid betaine, alkyl betaines (eg, lauryl betaine), amide betaines, sulfobetaines, and the like. It is done. Moreover, those salts are mentioned. Examples of the salt include sodium salt and potassium salt, but are not limited to these examples.
ポリオキシアルキレンフィトステロールとして、POE付加モル数20〜50程度のものが好ましい。 As the polyoxyalkylene phytosterol, those having a POE addition mole number of about 20 to 50 are preferable.
これら界面活性剤としては、特にポリオキシエチレンフィトステロール、ラウリン酸カリウム、ラウリルベタイン等が好ましい。 As these surfactants, polyoxyethylene phytosterol, potassium laurate, lauryl betaine and the like are particularly preferable.
これら界面活性剤の配合量は、角栓再生抑制剤中に0.001〜20質量%が好ましく、より好ましくは0.05〜5質量%である。0.001質量%未満では配合成分としての効果を十分に発揮することができず、一方、20質量%を超えて配合しても、配合量に見合った効果の増大は望めない。 The blending amount of these surfactants is preferably 0.001 to 20% by mass, more preferably 0.05 to 5% by mass in the horn plug regeneration inhibitor. If it is less than 0.001% by mass, the effect as a blending component cannot be sufficiently exhibited. On the other hand, even if it exceeds 20% by mass, an increase in the effect commensurate with the blending amount cannot be expected.
[抗肌荒れ剤]
本発明で用いる角栓再生抑制剤には、さらに抗肌荒れ剤を配合するのが好ましい。抗肌荒れ剤としては、一般に皮膚外用剤に用いられ得る抗肌荒れ効果を奏する成分であれば特に限定されるものでなく、例えば、トラネキサム酸、トラネキサム酸メチルアミド、1−ピペリジンプロピオン酸、ビタミンE−アセテート、グリセリン、キシリトール、エリスリトール、ポリオキシエチレン/ポリオキシプロピレン/ジメチルエーテル(=「PEG/PPGジメチルエーテル」)、パントテニルエチルエーテル、あるいはこれらの塩(ナトリウム塩、カリウム塩等)が挙げられる。また植物エキス(オトギリソウ、カミツレ等)も挙げられる。中でも、トラネキサム酸(塩)、PEG/PPGジメチルエーテル、パントテニルエチルエーテル等が好ましい。なおPEG/PPGジメチルエーテルは、PEGとPPGのモル比が、それぞれ1:2〜5:1程度のものが好ましく用いられる。
[Anti-skin roughening agent]
It is preferable that an anti-skin roughening agent is further added to the horn plug regeneration inhibitor used in the present invention. The anti-skin roughening agent is not particularly limited as long as it is a component that exhibits an anti-skin roughening effect that can be generally used in a topical skin preparation. For example, tranexamic acid, tranexamic acid methylamide, 1-piperidinepropionic acid, vitamin E-acetate Glycerin, xylitol, erythritol, polyoxyethylene / polyoxypropylene / dimethyl ether (= “PEG / PPG dimethyl ether”), pantothenyl ethyl ether, or salts thereof (sodium salt, potassium salt, etc.). Moreover, plant extracts (hypericum, chamomile, etc.) are also mentioned. Of these, tranexamic acid (salt), PEG / PPG dimethyl ether, pantothenyl ethyl ether, and the like are preferable. The PEG / PPG dimethyl ether preferably has a PEG / PPG molar ratio of about 1: 2 to 5: 1.
抗肌荒れ剤の配合量は、角栓再生抑制剤中に0.001〜20質量%が好ましく、より好ましくは0.05〜5質量%である。0.001質量%未満では抗肌荒れ成分としての効果を十分に発揮することができず、一方、20質量%を超えて配合しても、配合量に見合った効果の増大は望めない。
本発明に用いる角栓再生抑制剤には、本発明の効果を損なわない範囲で、通常、化粧品や医薬品等の皮膚外用剤に用いられる他の任意添加成分、例えば、油脂、ロウ類、炭化水素油、高級脂肪酸、高級アルコール、合成エステル油、シリコーン油、水溶性高分子、キレート剤、低級アルコール、多価アルコール、pH調整剤、酸化防止剤、粉末成分、香料、水等を必要に応じて適宜配合することができる。ただしこれら例示に限定されるものでない。
The blending amount of the anti-skin roughening agent is preferably 0.001 to 20% by mass, more preferably 0.05 to 5% by mass in the horn plug regeneration inhibitor. If it is less than 0.001% by mass, the effect as an anti-skin rough component cannot be sufficiently exhibited. On the other hand, even if it exceeds 20% by mass, an increase in the effect commensurate with the compounding amount cannot be expected.
For the horn plug regeneration inhibitor used in the present invention, other optional additives usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, fats and oils, waxes, hydrocarbons, etc., within the range not impairing the effects of the present invention. Oil, higher fatty acid, higher alcohol, synthetic ester oil, silicone oil, water-soluble polymer, chelating agent, lower alcohol, polyhydric alcohol, pH adjuster, antioxidant, powder component, perfume, water, etc. as required It can mix | blend suitably. However, it is not limited to these examples.
本発明に用いる角栓再生抑制剤の剤型は、特に限定されるものでなく、液状製剤、ゲル状製剤、クリーム、シート含浸製剤等として用いることができるが、特に液状製剤が好ましい。なお角栓再生抑制剤はpH3.0〜8.0程度とするのが好ましい。 The dosage form of the horn plug regeneration inhibitor used in the present invention is not particularly limited and can be used as a liquid preparation, a gel preparation, a cream, a sheet-impregnated preparation, and the like, but a liquid preparation is particularly preferable. In addition, it is preferable that the angle plug regeneration inhibitor has a pH of about 3.0 to 8.0.
<本発明の角栓再生抑制方法およびキット>
本発明では、上記皮膚洗浄料を用いて皮膚を洗浄した後、上記角栓再生抑制剤を皮膚に適用することで、極めて効果的に角栓再生を抑制することができる。肌への適用方法は、コットン等に含浸させて塗布する、スプレー等で噴霧する、等、剤型に応じて適宜行うことができる。また上記洗浄料と角栓再生抑制剤をセットにした化粧料キットとして販売することにより、簡便に使用することができる。
<Method and kit for inhibiting regeneration of horn plug of the present invention>
In this invention, after washing | cleaning skin using the said skin washing | cleaning material, the square plug regeneration inhibitor can be suppressed very effectively by applying the said square plug regeneration inhibitor to skin. The method of application to the skin can be appropriately performed depending on the dosage form, such as impregnation with cotton or the like, application by spraying, or the like. Moreover, it can be conveniently used by selling as a cosmetic kit in which the above-mentioned cleaning agent and a keratin plug regeneration inhibitor are set.
以下に実施例を挙げて本発明をさらに具体的に説明するが、本発明はこれによってなんら限定されるものではない。配合量は特記しない限りすべて質量%である。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited thereto. Unless otherwise specified, all the amounts are mass%.
(実施例1:ヒト試験による、皮膚洗浄料と角栓再生抑制剤の相乗効果)
1.試料
本実施例で用いた皮膚洗浄料、角栓再生抑制剤は以下のとおりである。
(Example 1: Synergistic effect of skin cleanser and horn plug regeneration inhibitor by human test)
1. Sample The skin cleansing agent and the horn plug regeneration inhibitor used in this example are as follows.
≪皮膚洗浄料(洗浄オイル)≫
ミネラルオイル 67.54(質量%)
ジフェニルシロキシフェニルトリメチコン 2
エタノール 1
イソステアリルアルコール 1
イソオクタン酸セチル 20
ジイソステアリン酸ポリエチレングリコール−12 5
ジイソステアリン酸ポリエチレングリコール−8 1
モノステアリン酸ポリエチレングリコール−10 2
テトラヒドロキシプロピルエチレンジアミン 0.01
ジブチルヒドロキシトルエン 0.05
イオン交換水 0.4
≪Skin cleansing oil (cleaning oil) ≫
Mineral oil 67.54 (mass%)
Diphenylsiloxyphenyl trimethicone 2
Ethanol 1
Isostearyl alcohol 1
Cetyl isooctanoate 20
Polyethylene glycol diisostearate-12 5
Polyethylene glycol diisostearate-8 1
Polyethylene glycol monostearate-10 2
Tetrahydroxypropylethylenediamine 0.01
Dibutylhydroxytoluene 0.05
Ion exchange water 0.4
≪角栓再生抑制剤(「製剤1」)。pH4.1≫
コハク酸 0.5(質量%)
乳酸 1
トラネキサム酸 1
エタノール 5
グリセリン 5
ジプロピレングリコール 5
PEG/PPG−14/7−ジメチルエーテル 1
水酸化カリウム 0.135
ポリオキシエチレンフィトステロール 2
グリシン 0.1
イオン交換水 残余
≪Square plug regeneration inhibitor (“Formulation 1”). pH 4.1 >>
Succinic acid 0.5 (mass%)
Lactic acid 1
Tranexamic acid 1
Ethanol 5
Glycerin 5
Dipropylene glycol 5
PEG / PPG-14 / 7-dimethyl ether 1
Potassium hydroxide 0.135
Polyoxyethylene phytosterol 2
Glycine 0.1
Ion exchange water
2.評価試験方法
[試験(1):製剤1のみ使用]
30代〜40代の比較的角栓の目立つ男性4名により、角栓の再生抑制試験を実施した。角栓の観察は、鼻頂部の適当なエリアに枠紙を貼り、ビデオマイクロスコープ(VMS。「キーエンス VHX−100」)観察にて行った。上記領域に対して、スライドグラス(マツナミ APSコート付き、s8444)に接着剤(「アロンアルファA」;三共)を数滴たらした後、その接着剤塗布面側を密着させた。10分間経過後にゆっくりとスライドグラスを剥離して角栓を除去した。再度VMS観察によって、完全に角栓を除去できた毛穴を特定し、これら特定した毛穴について、以降、角栓が再生してくる経過を観察した。ここで、製剤を使用しない状態(コントロール)での角栓再生の経過と、製剤を連用塗布したときの角栓再生の経過を比較した。
2. Evaluation Test Method [Test (1): Use only Formulation 1]
Four males in their 30s to 40s who are relatively conspicuous with plugs were subjected to a regeneration inhibition test of the plugs. The square plugs were observed by attaching a frame paper to an appropriate area of the top of the nose and observing with a video microscope (VMS, “Keyence VHX-100”). After dropping several drops of adhesive (“Aron Alpha A”; Sankyo) on a slide glass (with matsunami APS coat, s8444), the adhesive application surface side was brought into close contact with the above region. After 10 minutes, the slide glass was slowly peeled off to remove the square plug. The pores from which the horn plugs were completely removed were identified by VMS observation again, and the progress of regeneration of the horn plugs was observed for these identified pores. Here, the progress of regeneration of the horn plug when the preparation was not used (control) was compared with the progress of regeneration of the horn plug when the preparation was continuously applied.
製剤1:1日2回、2mLずつコットン(資生堂ビューティーアップコットン)に取り、VMS観察部位である鼻頂部を含む小鼻および頬を中心とした半顔に塗布し、3週間連用した。 Formulation 1: Take up 2 ml of cotton (Shiseido Beauty Up Cotton) twice a day and apply to the half face including the top of the nose and cheek, which is the VMS observation site, for 3 weeks.
[試験(2):皮膚洗浄料と製剤1との併用]
上記製剤1に皮膚洗浄料を組み合せた試験(2)を、上記試験(1)と同様に塗布する実験を、同一の被験者4名で実施した。皮膚洗浄料は、充分、成分をふき取った後に、製剤(1)を適用した。
[Test (2): Combination of skin cleanser and formulation 1]
An experiment in which the test (2) in which the preparation 1 was combined with a skin cleanser was applied in the same manner as in the test (1) was performed by the same four subjects. For the skin cleansing agent, the preparation (1) was applied after the components were sufficiently wiped off.
なお、4名のうち1名についてはVMSでの観察を実施せず、連用塗布のみを行った。 In addition, about 1 person among 4 persons, observation by VMS was not implemented but only continuous application | coating was performed.
<評価>
経時で同一毛穴の角栓の成長を比較し、製剤1(試験(2)では皮膚洗浄料併用。以下同)を使用しない状態(コントロール)での角栓成長に比べ、製剤1を塗布したときの角栓成長(=毛穴が詰まる)が遅かったものを勝ち、コントロールと製剤1塗布時とで角栓成長がほぼ同じ程度のものを引き分け、製剤1を使用しない状態(コントロール)での角栓成長に比べ、製剤1を塗布したときの角栓成長(=毛穴が詰まる)が速かったものを負けとして、4名分の比較を行った。結果を表1に示す。
<Evaluation>
Comparing the growth of square plugs with the same pore over time, when formulation 1 was applied compared to the growth of square plugs without using formulation 1 (in combination with skin cleanser in test (2), the same applies hereinafter) Horn plug growth (= clogged pores) was won, and those with the same growth rate were drawn between the control and the formulation 1 application, and the horn plug in the state where the formulation 1 was not used (control) Compared to the growth, a case where the growth of the horn plug when the formulation 1 was applied (= the pores were clogged) was lost, and a comparison was made for four persons. The results are shown in Table 1.
なお、最初に角栓が完全に除去でき比較できる毛穴の数が試験によって異なるため、試験(1)と試験(2)で評価した毛穴の数は異なっている。被験者4名合計で、試験(1)では22勝3敗8分けであったものが、試験(2)において洗浄オイルとの組み合せることにより、43勝4敗8分けとなった。表2に勝ちのみの率を算出した結果を示すが、その率が66.7%から78.2%へと上昇しており、特に若い被験者、例えばNo.2とNo.3で効果が高まっていた。 The number of pores evaluated in Test (1) and Test (2) is different because the number of pores that can be completely removed and compared can be different depending on the test. A total of 4 subjects, who were 22 wins and 3 losses in the test (1), became 8 wins in 43 wins and 4 losses when combined with cleaning oil in the test (2). Table 2 shows the result of calculating the win-only rate. The rate has increased from 66.7% to 78.2%. 2 and No. The effect was increasing at 3.
また、角栓のVMS観察を実施しなかった被験者1名を加えての問診(計5名)の結果では、3週間後に角栓が詰まるのが遅くなったと実感できた人数は、製剤1の塗布だけでは5名中1名のみであった。一方、洗浄料と組合せることで角栓の詰まるのが遅くなったと実感できたのは、5名中1週間後で2名、2週間後で3名、3週間後では4名となり、実効感がかなり高まったことが分かった。肌状態についても、小鼻および頬について塗布側ですべすべする、うるおうといった声があり、肌状態についても良くなっていた。 In addition, as a result of the interview (total of 5 subjects) including one subject who did not perform VMS observation of horn plugs, the number of people who could feel that plugging of horn plugs was delayed after 3 weeks was Only 1 out of 5 people was applied. On the other hand, when combined with the cleaning agent, the fact that the plugging of the horn plugs was delayed was realized in 2 people in 1 week out of 5 people, 3 in 2 weeks, and 4 in 3 weeks. It turned out that the feeling increased considerably. Regarding the skin condition, there was a voice that the nose and cheeks were smooth and moisturized on the application side, and the skin condition was also improved.
(実施例2:角栓再生抑制剤のスクリーニング)
実施例1で記載の方法に準じて得られた角栓を用いて、以下の表3に示す評価薬剤を用いて、角栓再生抑制効果についてスクリーニングを行った。
(Example 2: Screening of horn plug regeneration inhibitor)
Using the horn plug obtained according to the method described in Example 1, screening was performed for the effect of inhibiting horn plug regeneration using the evaluation drugs shown in Table 3 below.
すなわち、スライドグラスに接着剤(「アロンアルファA」)を数滴たらした後、その接着剤塗布面側を被験者の鼻頂部の一部領域に密着させた。10分間経過後にゆっくりとスライドグラスを剥離して角栓を得た。 That is, after dropping several drops of adhesive (“Aron Alpha A”) on the slide glass, the adhesive application surface side was brought into close contact with a partial region of the subject's nasal apex. After 10 minutes, the slide glass was slowly peeled off to obtain a square plug.
このようにして得たスライドグラス上の角栓を、カッター等で接着面から切り出し、カバーグラス上に敷いた両面テープの上に接着させた。それを5mLシャーレに入れ、表3に示す評価薬剤を含む水溶液(1%水溶液)を加えた。実体顕微鏡、SEMにより、角栓の経時での変化を観察し、角栓の崩壊程度に応じその形態を以下の4段階で評価した。なお評価は実体顕微鏡法、SEM法による評価を総合評価した。
(評価基準)
ランク0:変化なし(角栓の表面に全く変化が認められない)
ランク1:やや変化が認められる(角栓の表面が若干不鮮明になるなど若干の変化が認められる)
ランク2:変化あり(角栓の表面に明らかな変化が認められる)
ランク3:かなり変化あり(角栓の表面が崩れるなど、凹凸変化が顕著である)
(評価液)
評価液は表3に示す評価薬剤含む水溶液(1質量%含有水溶液)を用いた。
The square plug on the slide glass thus obtained was cut out from the adhesive surface with a cutter or the like and adhered onto a double-sided tape laid on the cover glass. It was put into a 5 mL petri dish, and an aqueous solution (1% aqueous solution) containing an evaluation agent shown in Table 3 was added. The change of the horn plug over time was observed with a stereomicroscope and SEM, and its form was evaluated according to the following four steps according to the degree of collapse of the horn plug. In addition, evaluation evaluated comprehensively the evaluation by a stereoscopic microscope method and a SEM method.
(Evaluation criteria)
Rank 0: No change (no change is observed on the surface of the plug)
Rank 1: Some changes are observed (Slight changes are observed, such as the surface of the square plug being slightly blurred)
Rank 2: There is a change (a clear change is observed on the surface of the plug)
Rank 3: There is considerable change (the unevenness change is remarkable, such as the surface of the square plug is broken)
(Evaluation solution)
The evaluation solution used was an aqueous solution containing 1% of the evaluation agent shown in Table 3 (1% by mass-containing aqueous solution).
以下に、さらに本発明の処方例を示す。
<皮膚洗浄料(処方例1〜2)>
(処方例1:皮膚洗浄料)
(配 合 成 分) (質量%)
(1)流動パラフィン 62.0
(2)2−エチルヘキサン酸ペンタエリスリトール 10.0
(3)POE(8)オレエート(HLB=9、液状) 10.0
(4)POE(20)グリセリルトリイソステアレート 10.0
(HLB=7、液状)
(5)N,N,N’,N’−テトラキス(2−ヒドロキシプロピル)
エチレンジアミン 3.0
(6)精製水 5.0
Below, the formulation example of this invention is shown further.
<Skin Cleansing (Prescription Examples 1-2)>
(Formulation example 1: skin cleansing agent)
(Mixed component) (mass%)
(1) Liquid paraffin 62.0
(2) 2-Ethylhexanoic acid pentaerythritol 10.0
(3) POE (8) oleate (HLB = 9, liquid) 10.0
(4) POE (20) glyceryl triisostearate 10.0
(HLB = 7, liquid)
(5) N, N, N ′, N′-tetrakis (2-hydroxypropyl)
Ethylenediamine 3.0
(6) Purified water 5.0
(処方例2:皮膚洗浄料)
(配 合 成 分) (質量%)
(1)スクワラン 残 余
(2)2−エチルヘキサン酸トリメチロールプロパン 10.0
(3)POE(12)オレエート(HLB=7、液状) 2.0
(4)POE(20)グリセリルトリイソステアレート 8.0
(HLB=7、液状)
(5)POE(50)硬化ヒマシ油モノイソステアレート 3.0
(HLB=12、ペースト状)
(6)N,N,N’,N’−テトラキス(2−ヒドロキシプロピル)
エチレンジアミン 0.1
(7)ビタミンE 0.05
(8)BHT 0.05
(9)精製水 2
(製法)
室温にて常温液状油分と界面活性剤とを混合・攪拌して均一にした後、水性成分を添加し混合・攪拌し均一にしてサンプルを調製する。
(Formulation example 2: skin cleansing agent)
(Mixed component) (mass%)
(1) Squalane residue (2) 2-methylhexanoic acid trimethylolpropane 10.0
(3) POE (12) oleate (HLB = 7, liquid) 2.0
(4) POE (20) glyceryl triisostearate 8.0
(HLB = 7, liquid)
(5) POE (50) hydrogenated castor oil monoisostearate 3.0
(HLB = 12, paste)
(6) N, N, N ′, N′-tetrakis (2-hydroxypropyl)
Ethylenediamine 0.1
(7) Vitamin E 0.05
(8) BHT 0.05
(9) Purified water 2
(Manufacturing method)
A room-temperature liquid oil and a surfactant are mixed and stirred at room temperature to be uniform, and then an aqueous component is added and mixed and stirred to prepare a sample.
<角栓再生抑制剤(処方例3〜11)>
(処方例3:化粧水)
(配 合 成 分) (質量%)
A.
エタノール 5.0
ポリオキシエチレンフィトステロール 2.0
PPG−13デシルテトラデセス−24 0.2
2−エチルヘキシル−P−ジメチルアミノベンゾエート 0.18
香料 0.05
B.
1,3−ブチレングリコール 9.5
ピロリドンカルボン酸ナトリウム 0.5
キシリトール 0.5
ニコチン酸アミド 0.3
グリセリン 5.0
トリメチルグリシン 5.0
トラネキサム酸 1.0
リジン 0.05
コハク酸 0.5
精製水 残 余
(製法)
Aのアルコール相をBの水相に添加し、可溶化して化粧水を得る。
<Square plug regeneration inhibitor (Prescription Examples 3 to 11)>
(Formulation example 3: lotion)
(Mixed component) (mass%)
A.
Ethanol 5.0
Polyoxyethylene phytosterol 2.0
PPG-13 decyltetradeces-24 0.2
2-Ethylhexyl-P-dimethylaminobenzoate 0.18
Fragrance 0.05
B.
1,3-butylene glycol 9.5
Sodium pyrrolidonecarboxylate 0.5
Xylitol 0.5
Nicotinamide 0.3
Glycerin 5.0
Trimethylglycine 5.0
Tranexamic acid 1.0
Lysine 0.05
Succinic acid 0.5
Purified water residue (production method)
The alcohol phase of A is added to the aqueous phase of B and solubilized to obtain a lotion.
(処方例4:乳液(ペムラン乳化系))
(配 合 成 分) (質量%)
A.油相
ジメチルポリシロキサン 0.5
デカメチルシクロペンタシロキサン 1
ホホバ油 0.5
ポリオキシエチレンフィトステロール 0.2
B.水相
トラネキサム酸 1
ニンジンエキス 0.5
アルキル変性カルボキシビニルポリマー 0.05
カルボキシビニルポリマー 0.3
アラビアガム 0.05
エチルアルコール 8
エデト酸三ナトリウム 0.1
メチルパラベン 0.1
フェノキシエタノール 0.2
クエン酸 0.05
イオン交換水 残 余
C.中和
水酸化カリウム 0.15
(製法)
溶解した(B)相に、溶解した(A)相を添加し、乳化後、(C)相で中和し、乳液を得る。
(Formulation Example 4: Emulsion (Pemlan Emulsion System))
(Mixed component) (mass%)
A. Oil phase Dimethylpolysiloxane 0.5
Decamethylcyclopentasiloxane 1
Jojoba oil 0.5
Polyoxyethylene phytosterol 0.2
B. Water phase tranexamic acid 1
Carrot extract 0.5
Alkyl-modified carboxyvinyl polymer 0.05
Carboxyvinyl polymer 0.3
Gum arabic 0.05
Ethyl alcohol 8
Edetate trisodium 0.1
Methylparaben 0.1
Phenoxyethanol 0.2
Citric acid 0.05
Ion exchange water Residual C.I. Neutralization Potassium hydroxide 0.15
(Manufacturing method)
The dissolved (A) phase is added to the dissolved (B) phase, emulsified, and then neutralized with the (C) phase to obtain an emulsion.
(処方例5:乳液)
(配 合 成 分) (質量%)
(1)ステアリン酸 2.0
(2)ラウリン酸 0.5
(3)セチルアルコール 1.5
(4)ワセリン 5.0
(5)流動パラフィン 10.0
(6)POE(10モル)モノオレイン酸エステル 2.0
(7)ポリエチレングリコール(1500) 3.0
(8)トリエタノールアミン 1.0
(9)水酸化カリウム 0.05
(10)カルボキシビニルポリマー 0.05
(11)亜硫酸水素ナトリウム 0.01
(12)防腐剤 適 量
(13)香料 適 量
(14)クエン酸 0.05
(15)1−ピペリジンプロピオン酸 0.05
(16)イオン交換水 残 余
(製法)
(16)の一部に(10)を溶解する(A相)。残りの(16)に(7)、(8)、(9)、(11)、(14)、(15)を加え、加熱溶解した70℃に保つ(水相)。一方、(1)〜(6)、(12)、(13)を混合し加熱融解して70℃に保つ(油相)。水相に油相を加え予備乳化を行い、A相を加えホモミキサーで均一に乳化し、乳化後よくかき混ぜながら30℃まで冷却して乳液を得る。
(Formulation Example 5: Emulsion)
(Mixed component) (mass%)
(1) Stearic acid 2.0
(2) Lauric acid 0.5
(3) Cetyl alcohol 1.5
(4) Vaseline 5.0
(5) Liquid paraffin 10.0
(6) POE (10 mol) monooleate 2.0
(7) Polyethylene glycol (1500) 3.0
(8) Triethanolamine 1.0
(9) Potassium hydroxide 0.05
(10) Carboxyvinyl polymer 0.05
(11) Sodium bisulfite 0.01
(12) Preservative appropriate amount (13) Fragrance proper amount (14) Citric acid 0.05
(15) 1-piperidinepropionic acid 0.05
(16) Residual ion-exchanged water (Production method)
(10) is dissolved in a part of (16) (A phase). (7), (8), (9), (11), (14), and (15) are added to the remaining (16), and the mixture is kept at 70 ° C. by heating and dissolving (aqueous phase). On the other hand, (1) to (6), (12) and (13) are mixed, heated and melted, and kept at 70 ° C. (oil phase). Preliminarily emulsify by adding an oil phase to the aqueous phase, add phase A, uniformly emulsify with a homomixer, and cool to 30 ° C. while stirring well after emulsification to obtain an emulsion.
(処方例6:乳液)
(配 合 成 分) (質量%)
(1)マイクロクリスタリンワックス 1.0
(2)ミツロウ 2.0
(3)ラノリン 20.0
(4)流動パラフィン 10.0
(5)スクワラン 5.0
(6)ソルビタンセスキオレイン酸エステル 4.0
(7)POE(20モル)ソルビタンモノオレイン酸エステル 1.0
(8)ラウリルベタイン 0.1
(9)プロピレングリコール 7.0
(10)L−アルギニン塩酸塩 5.0
(11)グリセリン 3.0
(12)グリコール酸 0.05
(13)亜硫酸水素ナトリウム 0.01
(14)防腐剤 適 量
(15)香料 適 量
(16)イオン交換水 残 余
(製法)
(16)に(8)〜(13)を加え、加熱して70℃に保つ(水相)。一方、(1)〜(7)、(14)、(15)を混合し加熱融解して70℃に保つ(油相)。油相をかき混ぜながら水相を徐々に加え、ホモミキサーで均一に乳化した後、よくかき混ぜながら30℃まで冷却し、乳液を得る。
(Formulation Example 6: Latex)
(Mixed component) (mass%)
(1) Microcrystalline wax 1.0
(2) Beeswax 2.0
(3) Lanolin 20.0
(4) Liquid paraffin 10.0
(5) Squalane 5.0
(6) Sorbitan sesquioleate ester 4.0
(7) POE (20 mol) sorbitan monooleate 1.0
(8) Lauryl betaine 0.1
(9) Propylene glycol 7.0
(10) L-arginine hydrochloride 5.0
(11) Glycerin 3.0
(12) Glycolic acid 0.05
(13) Sodium bisulfite 0.01
(14) Preservative appropriate amount (15) Fragrance appropriate amount (16) Ion-exchanged water residue (Production method)
Add (8) to (13) to (16) and heat to keep at 70 ° C. (aqueous phase). On the other hand, (1) to (7), (14) and (15) are mixed, heated and melted, and kept at 70 ° C. (oil phase). The water phase is gradually added while stirring the oil phase, and the mixture is uniformly emulsified with a homomixer, and then cooled to 30 ° C. while stirring well to obtain an emulsion.
(処方例7:乳液(W/O乳化タイプ))
(配 合 成 分) (質量%)
(1)イソプロピルアルコール 10.0
(2)ジイソステアリン酸ジグリセリル 0.5
(3)POE変性ジメチルポリシロキサン 1.0
(4)ポリオキシエチレンフィトステロール 0.5
(5)オクタメチルシクロテトラシロキサン 25.0
(6)デカメチルシクロペンタシロキサン 15.0
(7)トリメチルシロキシケイ酸 5.0
(8)ユーカリ油 3.0
(9)香料 0.05
(10)ジプロピレングリコール 2.0
(11)フェノキシエタノール 0.3
(12)エデト酸3ナトリウム 0.1
(13)イオン交換水 残 余
(14)塩化カリウム 0.5
(15)トラネキサム酸 0.5
(16)乳酸 0.05
(製法)
(1)〜(9)を加熱溶解し(油相)、(10)〜(16)を溶解し(水相)、油相に水相を添加し、乳化し、乳液を得る。
(Formulation example 7: emulsion (W / O emulsion type))
(Mixed component) (mass%)
(1) Isopropyl alcohol 10.0
(2) Diglyceryl diisostearate 0.5
(3) POE-modified dimethylpolysiloxane 1.0
(4) Polyoxyethylene phytosterol 0.5
(5) Octamethylcyclotetrasiloxane 25.0
(6) Decamethylcyclopentasiloxane 15.0
(7) Trimethylsiloxysilicic acid 5.0
(8) Eucalyptus oil 3.0
(9) Fragrance 0.05
(10) Dipropylene glycol 2.0
(11) Phenoxyethanol 0.3
(12) Trisodium edetate 0.1
(13) Residual ion exchange water (14) Potassium chloride 0.5
(15) Tranexamic acid 0.5
(16) Lactic acid 0.05
(Manufacturing method)
(1) to (9) are dissolved by heating (oil phase), (10) to (16) are dissolved (aqueous phase), the aqueous phase is added to the oil phase and emulsified to obtain an emulsion.
(処方例8:ゼリー)
(配 合 成 分) (質量%)
(A相)
95%エチルアルコール 10.0
POE(20モル)オクチルドデカノール 1.0
パントテニルエチルエーテル 0.1
ラウリルベタイン 0.05
ビタミンE−アセテート 0.05
防腐剤 適 量
(B相)
水酸化カリウム 0.1
(C相)
グリセリン 5.0
ジプロピレングリコール 10.0
亜硫酸水素ナトリウム 0.03
クエン酸 0.05
L−アルギニンマグネシウム塩 0.05
カルボキシビニルポリマー 0.2
イオン交換水 残 余
(製法)
A相、C相をそれぞれ均一に溶解し、C相にA相を加えて可溶化する。次いでB相を加えた後充填を行い、ゼリーを得る。
(Prescription Example 8: Jelly)
(Mixed component) (mass%)
(Phase A)
95% ethyl alcohol 10.0
POE (20 mol) octyldodecanol 1.0
Pantothenyl ethyl ether 0.1
Lauryl betaine 0.05
Vitamin E-acetate 0.05
Preservative appropriate amount (phase B)
Potassium hydroxide 0.1
(Phase C)
Glycerin 5.0
Dipropylene glycol 10.0
Sodium bisulfite 0.03
Citric acid 0.05
L-arginine magnesium salt 0.05
Carboxyvinyl polymer 0.2
Residual ion exchange water
A phase and C phase are uniformly dissolved, and A phase is added to C phase to solubilize. Then, after adding phase B, filling is performed to obtain a jelly.
(処方例9:O/Wクリーム)
(配 合 成 分) (質量%)
A.油相
セタノール 4.0
ワセリン 7.0
イソプロピルミリステート 8.0
スクワラン 15.0
ステアリン酸モノグリセリンエステル 2.2
POE(20)ソルビタンモノステアレート 2.8
ラウリルベタイン 0.05
5−エトキシサリチル酸 0.01
ビタミンEニコチネート 2.0
香料 0.3
酸化防止剤 適 量
防腐剤 適 量
B.水相
グリセリン 10.0
ヒアルロン酸ナトリウム 0.02
キシリトール 1.0
ジプロピレングリコール 4.0
PEG/PPG−14/7ジメチルエーテル 1.0
アラニン 3.0
エデト酸二ナトリウム 0.01
クエン酸 1.0
精製水 残 量
(製法)
A(油相)とB(水相)をそれぞれ70℃に加熱し、完全溶解した。次いで、Aを
Bに加えて、乳化機で乳化した。さらに、乳化物を熱交換機を用いて冷却して、
クリームを得る。
(Formulation example 9: O / W cream)
(Mixed component) (mass%)
A. Oil phase Cetanol 4.0
Vaseline 7.0
Isopropyl myristate 8.0
Squalane 15.0
Stearic acid monoglycerol ester 2.2
POE (20) sorbitan monostearate 2.8
Lauryl betaine 0.05
5-Ethoxysalicylic acid 0.01
Vitamin E Nicotinate 2.0
Fragrance 0.3
Antioxidant appropriate amount Preservative appropriate amount Aqueous phase Glycerin 10.0
Sodium hyaluronate 0.02
Xylitol 1.0
Dipropylene glycol 4.0
PEG / PPG-14 / 7 dimethyl ether 1.0
Alanine 3.0
Edetate disodium 0.01
Citric acid 1.0
Purified water residue (production method)
A (oil phase) and B (aqueous phase) were each heated to 70 ° C. and completely dissolved. Next, A was added to B and emulsified with an emulsifier. Furthermore, the emulsion is cooled using a heat exchanger,
Get a cream.
(処方例10:W/Oクリーム)
(配 合 成 分) (質量%)
(1)塩化ジメチルジステアリルアンモニウム処理ヘクトライト 2.0
(2)ポリオキシエチレン・メチルポリシロキサン重合体 0.1
(3)ラウリルベタイン 0.5
(4)流動パラフィン 10.0
(5)ワセリン 5.0
(6)オクタン酸セチル 20.0
(7)Lーグルタミン酸ソーダ 0.01
(8)ジプロピレングリコール 5.0
(9)メチルパラベン 0.2
(10)サリチル酸 1.0
(11)キシリトール 2.0
(12)イオン交換水 残 量
(製法)
(2)(3)(4)(6)を50℃に昇温した後、(5)を加え完全に溶解した油相パーツに(1)を加えて均一に分散を行ったものに、(12)へ(7)(8)(9)(10)(11)を溶解させた水相パーツを50℃に加温して添加を行い、HMにて均一分散した後、室温まで冷却し、W/Oクリームを得る。
(Formulation example 10: W / O cream)
(Mixed component) (mass%)
(1) Hectorite treated with dimethyl distearyl ammonium chloride 2.0
(2) Polyoxyethylene / methylpolysiloxane polymer 0.1
(3) Lauryl betaine 0.5
(4) Liquid paraffin 10.0
(5) Vaseline 5.0
(6) Cetyl octoate 20.0
(7) Sodium L-glutamate 0.01
(8) Dipropylene glycol 5.0
(9) Methylparaben 0.2
(10) Salicylic acid 1.0
(11) Xylitol 2.0
(12) Remaining amount of ion-exchanged water (production method)
(2) After the temperature of (3), (4) and (6) is raised to 50 ° C., (1) is added to the oil phase part completely dissolved by adding (5) and dispersed uniformly. 12) To (7) (8) (9) (10) (11) dissolved in water phase parts are heated to 50 ° C. and added, uniformly dispersed in HM, cooled to room temperature, W / O cream is obtained.
(処方例11:白濁化粧水)
(配 合 成 分) (質量%)
(1)α−オレフィンオリゴマー 2.0
(2)イソステアリルアルコール 0.5
(3)イソステアリン酸 0.8
(4)セスキイソステアリン酸ソルビタン 0.1
(5)POE(14)・POP(7)ジメチルエーテル 1.0
(6)ポリオキシエチレンフィトステロール 1.0
(7)酢酸DL−α−トコフェロール 0.05
(8)香料 適 量
(9)1,3−ブチレングリコール 5.0
(10)エタノール 5.0
(11)キサンタンガム 0.1
(12)コハク酸 0.5
(13)ジプロピレングリコール 5.0
(14)トラネキサム酸 1.0
(15)ヒアルロン酸ナトリウム 0.01
(16)ピロ亜硫酸ナトリウム 0.005
(17)フェノキシエタノール 0.5
(18)メタリン酸ナトリウム 0.05
(19)ラウリルジメチルアミノ酢酸ベタイン 0.2
(20)水酸化カリウム 0.2
(21)乳酸 1.0
(22)濃グリセリン 5.0
(23)精製水 残 量
(製法)
(1)から(8)を、70℃に加熱溶解し、攪拌混合し、温度を70℃に維持して攪拌を行いながら、(23)を徐々に添加して乳化を行い、水中油型乳化組成物を得る。得られた水中油型乳化組成物を、さらに(9)から(22)を含む水性処方中に添加し、攪拌により均一分散させて白濁化粧水を得る。
(Prescription Example 11: Cloudy lotion)
(Mixed component) (mass%)
(1) α-olefin oligomer 2.0
(2) Isostearyl alcohol 0.5
(3) Isostearic acid 0.8
(4) Sorbitan sesquiisostearate 0.1
(5) POE (14) / POP (7) dimethyl ether 1.0
(6) Polyoxyethylene phytosterol 1.0
(7) DL-α-tocopherol acetate 0.05
(8) Perfume appropriate amount (9) 1,3-butylene glycol 5.0
(10) Ethanol 5.0
(11) Xanthan gum 0.1
(12) Succinic acid 0.5
(13) Dipropylene glycol 5.0
(14) Tranexamic acid 1.0
(15) Sodium hyaluronate 0.01
(16) Sodium pyrosulfite 0.005
(17) Phenoxyethanol 0.5
(18) Sodium metaphosphate 0.05
(19) Lauryldimethylaminoacetic acid betaine 0.2
(20) Potassium hydroxide 0.2
(21) Lactic acid 1.0
(22) Concentrated glycerin 5.0
(23) Remaining amount of purified water (production method)
(1) to (8) are heated and dissolved at 70 ° C., stirred and mixed, and while stirring while maintaining the temperature at 70 ° C., (23) is gradually added to emulsify, and oil-in-water emulsification A composition is obtained. The obtained oil-in-water emulsion composition is further added to an aqueous formulation containing (9) to (22), and uniformly dispersed by stirring to obtain a cloudy lotion.
本発明により、非常に高い角栓再生抑制効果を奏する角栓再生抑制方法および角栓再生抑制キットが提供される。 INDUSTRIAL APPLICABILITY According to the present invention, there are provided a horn plug regeneration suppression method and a horn plug regeneration suppression kit that exhibit an extremely high effect of suppressing horn plug regeneration.
Claims (5)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011169751A JP5400105B2 (en) | 2011-08-03 | 2011-08-03 | Square plug regeneration suppression method and square plug regeneration suppression kit |
| PCT/JP2012/069823 WO2013018884A1 (en) | 2011-08-03 | 2012-08-03 | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit |
| CN201280048891.7A CN103857378B (en) | 2011-08-03 | 2012-08-03 | Angle plug regeneration inhibitor, angle plug regeneration inhibiting method, and horn plug regeneration inhibiting kit |
| KR1020147005183A KR101508168B1 (en) | 2011-08-03 | 2012-08-03 | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit |
| TW101128202A TWI481417B (en) | 2011-08-03 | 2012-08-03 | Inhibiting preparation against re-growth of pore-clogging plug, method of inhibiting re-growth of pore-clogging plug, and a kit for the use of inhibiting re-growth of pore-clogging plug |
| HK14111310.4A HK1197582B (en) | 2011-08-03 | 2012-08-03 | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011169751A JP5400105B2 (en) | 2011-08-03 | 2011-08-03 | Square plug regeneration suppression method and square plug regeneration suppression kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013032319A true JP2013032319A (en) | 2013-02-14 |
| JP5400105B2 JP5400105B2 (en) | 2014-01-29 |
Family
ID=47788504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011169751A Expired - Fee Related JP5400105B2 (en) | 2011-08-03 | 2011-08-03 | Square plug regeneration suppression method and square plug regeneration suppression kit |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5400105B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014155854A1 (en) * | 2013-03-27 | 2014-10-02 | Murakami Hiroshi | Protein extraction agent and protein extraction method |
| JP2015113307A (en) * | 2013-12-12 | 2015-06-22 | クラシエホームプロダクツ株式会社 | Skin cleanser composition |
| JP2015197337A (en) * | 2014-03-31 | 2015-11-09 | 株式会社ナリス化粧品 | Screening method of material having horny plug formation suppressing effect |
| JP2018021084A (en) * | 2013-12-03 | 2018-02-08 | 博 村上 | Liquid cleansing agent for horn plug removal |
| JP2019131507A (en) * | 2018-01-31 | 2019-08-08 | 株式会社コーセー | Skin external preparations or cosmetics |
| JP2021161112A (en) * | 2020-03-31 | 2021-10-11 | 株式会社コーセー | Composition |
| JP2022051529A (en) * | 2020-09-18 | 2022-03-31 | 株式会社コーセー | External preparation for skin |
| JPWO2022091318A1 (en) * | 2020-10-30 | 2022-05-05 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04360830A (en) * | 1991-06-10 | 1992-12-14 | Kao Corp | Keratotic reproduction inhibitor |
| JP2002241260A (en) * | 2001-02-19 | 2002-08-28 | Shiseido Co Ltd | Cosmetic for removing keratotic plug |
| JP2004075575A (en) * | 2002-08-12 | 2004-03-11 | Naris Cosmetics Co Ltd | Cornoid lamella resolvent |
| JP2004083541A (en) * | 2001-09-28 | 2004-03-18 | Shiseido Co Ltd | Agent for external use to skin |
| JP2006225266A (en) * | 2005-02-15 | 2006-08-31 | Shiseido Co Ltd | Square plug removal composition |
| JP2006298866A (en) * | 2005-04-25 | 2006-11-02 | Pola Chem Ind Inc | External preparation for cleansing skin |
| JP2009143878A (en) * | 2007-12-18 | 2009-07-02 | Pola Chem Ind Inc | Keratotic plug removing composition |
-
2011
- 2011-08-03 JP JP2011169751A patent/JP5400105B2/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04360830A (en) * | 1991-06-10 | 1992-12-14 | Kao Corp | Keratotic reproduction inhibitor |
| JP2002241260A (en) * | 2001-02-19 | 2002-08-28 | Shiseido Co Ltd | Cosmetic for removing keratotic plug |
| JP2004083541A (en) * | 2001-09-28 | 2004-03-18 | Shiseido Co Ltd | Agent for external use to skin |
| JP2004075575A (en) * | 2002-08-12 | 2004-03-11 | Naris Cosmetics Co Ltd | Cornoid lamella resolvent |
| JP2006225266A (en) * | 2005-02-15 | 2006-08-31 | Shiseido Co Ltd | Square plug removal composition |
| JP2006298866A (en) * | 2005-04-25 | 2006-11-02 | Pola Chem Ind Inc | External preparation for cleansing skin |
| JP2009143878A (en) * | 2007-12-18 | 2009-07-02 | Pola Chem Ind Inc | Keratotic plug removing composition |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012055672; 新しい化粧品素材の効能・効果・作用(下) , 19980831, pp.444-447 * |
| JPN6012055673; 新化粧品ハンドブック , 20061030, pp.426-428 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014155854A1 (en) * | 2013-03-27 | 2014-10-02 | Murakami Hiroshi | Protein extraction agent and protein extraction method |
| JP2018021084A (en) * | 2013-12-03 | 2018-02-08 | 博 村上 | Liquid cleansing agent for horn plug removal |
| JP2015113307A (en) * | 2013-12-12 | 2015-06-22 | クラシエホームプロダクツ株式会社 | Skin cleanser composition |
| JP2015197337A (en) * | 2014-03-31 | 2015-11-09 | 株式会社ナリス化粧品 | Screening method of material having horny plug formation suppressing effect |
| JP2019131507A (en) * | 2018-01-31 | 2019-08-08 | 株式会社コーセー | Skin external preparations or cosmetics |
| JP7032945B2 (en) | 2018-01-31 | 2022-03-09 | 株式会社コーセー | External skin preparation or cosmetics |
| JP2021161112A (en) * | 2020-03-31 | 2021-10-11 | 株式会社コーセー | Composition |
| JP2022051529A (en) * | 2020-09-18 | 2022-03-31 | 株式会社コーセー | External preparation for skin |
| JPWO2022091318A1 (en) * | 2020-10-30 | 2022-05-05 | ||
| JP7725495B2 (en) | 2020-10-30 | 2025-08-19 | 株式会社 資生堂 | Water-in-oil emulsion composition containing salicylic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5400105B2 (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5400105B2 (en) | Square plug regeneration suppression method and square plug regeneration suppression kit | |
| KR101508168B1 (en) | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit | |
| JP5400196B2 (en) | Square plug regeneration inhibitor | |
| JP5773783B2 (en) | Moisturizing cosmetics | |
| JP7387500B2 (en) | Oil-in-water emulsion composition | |
| JP2006206575A (en) | Pigmentation preventing or improving agent | |
| KR20170081219A (en) | Cleansing compositions | |
| JP3780257B2 (en) | Dermal composition for oil and fat suppression | |
| JP6904754B2 (en) | Oil-in-water emulsified composition | |
| JP5514268B2 (en) | Pigmentation preventing or improving agent | |
| JP6087099B2 (en) | Topical skin preparation | |
| JP2004002289A (en) | Parakeratosis inhibitor | |
| JP6967369B2 (en) | Emulsifying composition | |
| JP3931295B2 (en) | Emulsified cosmetic for hairdressing | |
| JPH11263721A (en) | Oil-in-water type gommage (peeling) cosmetic | |
| JP2021050155A (en) | Composition | |
| JP3568983B2 (en) | Hair restorer | |
| JP4129377B2 (en) | Hairdressing composition | |
| JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
| JP6830735B2 (en) | Emulsified skin external preparation | |
| JP2006273807A (en) | Cosmetic | |
| JP2020147538A (en) | Milky lotion-like skin cosmetic | |
| HK1197582B (en) | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit | |
| JP7086719B2 (en) | Skin cosmetics | |
| JPH1179937A (en) | Skin lotion for pimple treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130925 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131024 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5400105 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |